)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Amphastar Pharmaceuticals (AMPH) investor relations material
Amphastar Pharmaceuticals Wells Fargo 20th Annual Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Wells Fargo 20th Annual Healthcare Conference 2025 summary3 Sep, 2025
Company Overview, Strategy, and Business Model
Vertically integrated operations span R&D, manufacturing, and distribution, with 1,500 employees and over a decade as a public entity.
Dual growth strategies include organic pipeline expansion and inorganic growth via strategic acquisitions.
Focus on expanding proprietary pipeline to 50% and biosimilars to 35% by 2026, with ongoing business development.
Emphasis on quality, efficiency, and technology has led to rising net income margins and strong revenue growth from 2018 to 2024.
Revenue reached $732 million in 2024, with adjusted net income margin at 27.4%.
Pipeline Evolution, R&D, and Regulatory Updates
Substantial R&D investment of $351 million over five years supports a diverse and scalable product portfolio.
Six generic pipeline candidates in advanced stages, with several FDA approvals expected between late 2025 and 2026.
In-licensed three new peptide assets targeting oncology and ophthalmology, expanding into high-growth markets.
Iron sucrose launched with capacity constraints limiting market share to 25%, but competitive generic therapy status provides six-month exclusivity.
Teriparatide ANDA on track for Q4 GDUFA date, with AMP007 and other ANDA/BLA filings anticipated through 2026.
Key Products and Commercial Performance
BAQSIMI® acquisition expands the diabetes portfolio and international presence to 26 countries, with projected peak sales of $250–$275 million.
Baqsimi transitioned to full control, achieving double-digit script growth and high single-digit unit growth guidance for the year.
Primatene MISTⓇ, the only FDA-approved OTC asthma inhaler, surpassed $100 million in sales in 2024 and is forecasted for continued growth.
Primatene Mist posted 10% year-over-year growth, supported by DTC and physician sampling, with durability expected despite upcoming patent expiry.
Existing products provide a strong revenue base, with new launches supporting diversification.
Confidence in Baqsimi's $250M-$275M peak sales?
Primatene Mist growth strategy post-2026 patent?
Gross margin inflection point and key drivers?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Amphastar Pharmaceuticals earnings date
Q3 20255 Nov, 2025
Next Amphastar Pharmaceuticals earnings date
Q3 20255 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacture, and marketing of generic and proprietary injectable, inhalation, and intranasal products. The company focuses on producing pharmaceuticals for hospital, emergency, and clinical use, including treatments for respiratory conditions, diabetes, and pain management. Amphastar operates manufacturing and research facilities to support its product portfolio and pipeline development. Amphastar Pharmaceuticals Inc. is headquartered in Rancho Cucamonga, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage